Status
Conditions
Treatments
About
Heart failure is a growing throughout pathology in Europe. It is a public health issue and an economic issue. The management to be effective needs to be early but specific. Generic treatment (medication, rehabilitation, hygienic dietary measures) known for over 15 years and has demonstrated its effectiveness, come s'ajouter solutions specific, technically complex and expensive to implement. Because of the potential risk to the patient and their cost to the company, these new techniques need to be adapted to each case. The passage of a generic simple treatment for everyone in the single treatment tailored to each patient requires decision support tools for the clinician. These tools or decision trees are developed using mathematical and statistical models fed by all patient data (imaging, biology physiology ...) before and after implementation of treatment. Predictive response models of a treatment applied to a particular pathology can thus be generated.
It is this type of models applied in systolic heart failure complicated by mitral regurgitation and / or cardiac synchronization that will be generated in this project from 150 patients included in 3 European clinical studies (London, Brussels, Caen). In Caen we will include 30 patients in this single-center study
Full description
Heart failure (HF) is a clinical problem increasingly common throughout Europe, partly because of the aging population and increasing numbers of patients now survive after myocardial infarction [1, 2] . The IC is a progressive disease and when patients require hospitalization, long-term prognosis is poor [3]. The treatment of IC is focused on improving the work of the failing heart via the use of specific drugs, if necessary by cardiovascular interventions correcting structural lesions (mitral regurgitation) or correcting a disorganized contraction (therapy resynchronization). However, the IC is a disease complex with multiple factors pathophysiological interdependent making difficult treatment choices optimal or of a combination therapeutic optimal.
The technologies HPV predictive, such as tools for processing data, statistical models and simulations biophysical that incorporate these factors pathophysiological have tremendous potential to help improve our understanding of the response to treatment in the context of the IC. In particular, they have the potential to improve the selection of patients for cardiovascular interventions such as cardiac resynchronization therapy and / or that an intervention on the mitral valve [4].
Projects recent - European (HPV or Human physiological virtual) and national - have developed a large number of these technologies, but n'ont not been fully released into the environment clinic to help care for patients IC.
The objective of VP2HF project is to develop and validate in clinical settings computer modeling platform to integrate non-invasive clinical and imaging evidence acquired in patients with heart failure ( IC) for two reasons:
This is a pilot study to generate complete data sets used to parameterize the model calculations. All patients will have an accurate imaging assessment and a detailed assessment of bio-signals at times (time points) accurate (as shown above) with variations depending on the sustained cardiovascular procedure described below .
Preoperatively
Peri-interference Whatever the treatment envisaged by the surgical team in charge of processing (resynchronization, mitral clip, mitral valve repair or mitral valve replacement) operative techniques and monitoring procedures will be those normally used by operators.
Cardiac resynchronization therapy (CRT) can be considered that 70% of patients in our cohort eligible for a CRT are also eligible for this project. Invasive measurement of left ventricular pressure with and without stimulation may also be acquired to study the acute hemodynamic effects of CRT and to make comparisons with the extent of NBP in order to test and validate the noninvasive pressure estimates and mechanical modeling tools.
Repair and replacement of the mitral valve: It is expected that 30% of our cohort of patients have significant mitral regurgitation requiring intervention, mainly to repair the mitral valve and the occasional replacement of the mitral valve when the repair is unsuccessful. In some of these patients, the repair will be carried out by trans-catheter track and they will hemodynamic measurements in the aorta, the left ventricle and the left atrium before and after the repair of the mitral valve that will be used for the purposes of test and validate non-invasive estimates of pressure and mechanical modeling tools.
Immediately after surgery All patients will again echocardiography, non-invasive measurement of central blood pressure.
Followed at 6 months We will again perform , 6 months after surgery , complete postoperative evaluation unless cardiac MRI in patients with a CRT ( because this review is against - indicated ) .
in addition to standard care pathway exams non-invasive measurement of central blood pressure The non -invasive blood pressure management Centron Diagnostics uses a humeral standard oscillatory cuff estimate both the PA peripheral and central aortic pressure. For the patient, this is an experiment similar to that of an automatic blood pressure recording . All patients benefit from this measure .
Exams IRM3T to Cycéron (M0 and M6)
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
30 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal